Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer

To evaluate the efficacy and safety of maintenance therapy with Adebrelimab plus Apatinib for extensive stage small cell lung cancer after first-line induction of Adebrelimab plus chemotherapy.

Trial Details

NCT ID
NCT06480864
Phase
NA
Sponsor
Yunpeng Liu
Status
RECRUITING
Cancer Type
Small Cell (SCLC) Lung Cancer
Interventions
  • Adebrelimab Injection
  • Apatinib Mesylate Tablets
  • Carboplatin
  • Cisplatin
  • Etoposide
Locations (sample)
  • Shenyang, Liaoning, China|41.79222,123.43278
  • Shenyang, China|41.79222,123.43278

Key Eligibility Criteria

  • Participants voluntarily enrolled in this study and signed an informed consent form, were compliant and co-operated with follow-up visits;
  • Age 18 years and above, male and female;
  • Diagnosis of extensive stage small cell lung cancer (ES-SCLC) confirmed by histology or pathology (according to the American Veterans Lung Cancer A…
  • ECOG physical condition score is 0-2;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →